1. Roche Sequencing | United States
  2. NGS Oncology Assays
  3. AVENIO ctDNA Analysis Kits

AVENIO ctDNA Analysis Kits

Overview

The AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research.  These assays provide an end-to-end tumor profiling and longitudinal tumor burden monitoring solution.

Features and Benefits of AVENIO ctDNA Analysis Kits

  • Flexibility to match the right assay optimized for the right research goal
  • Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

...

AVENIO ctDNA Targeted Kit – Tumor Profiling

The AVENIO ctDNA Targeted Kit is a 17 gene (81kb) pan-cancer assay that detects biomarkers relevant for lung cancer and colorectal cancer (CRC). The Targeted panel, which contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines, is a practical and focused tumor profiling assay.

Learn more
...

AVENIO ctDNA Expanded Kit – Expanded Tumor Profiling

The AVENIO ctDNA Expanded Kit contains 77 genes (192kb), including those in NCCN guidelines, as well as emerging cancer biomarkers. The Expanded Kit is also a pan-cancer assay that’s optimized for lung cancer and CRC.

Learn more
...

AVENIO ctDNA Surveillance Kit – Longitudinal Tumor Burden Monitoring

The AVENIO ctDNA Surveillance Kit contains a 197 gene (198kb) panel that’s specifically designed and optimized for longitudinal tumor burden monitoring in lung cancer and CRC. The Surveillance kit also includes genes in NCCN Guidelines.

Learn more

References

1. National Comprehensive Cancer Network.  October 15, 2016.

2. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.

3. Data on file.

Contact Us

Contact your local Roche sales representative for more information.

Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. All other product names and trademarks are the property of their respective owners.